The Neurology Minute® podcast delivers a brief daily summary of what you need to know in the field of neurology, the latest science focused on the brain, and timely topics explored by leading neurologists and neuroscientists. From the American Academy of Neurology and hosted by Stacey Clardy, MD, PhD, FAAN, with contributions by experts from the Neurology® journals, Neurology Today®, Continuum®, and more.
Ptosis, ophthalmoplegia, unsteady gait, limb weakness and peripheral nerve symptoms make this a short but specialist neurology choice. Choose it for revision or clinic work where mitochondrial disease, POLG-related disease, polyneuropathy and myopathy need to stay connected despite an incomplete early picture.
Milk expression at work is physiology, not a favour squeezed between clinics. Protected 20–30 minute breaks every 2–3 hours, room access and rota planning reduce risks to supply and complications from insufficient expression.
EBV antibody work is mainly for neuroinflammatory diagnostic discussion. A single high result is not enough; persistent high responses over time may support MS differentiation from MOGAD or NMOSD when the clinical picture fits.
A stroke-code patient with recurrent transient deficit and new multifocal intracranial stenosis is not a routine pathway case. Open this first: link symptoms, vascular imaging, blood work and biopsy before deciding whether vasculitis, reversible cerebral vasoconstriction syndrome or refractory cerebrovascular events need escalation.
EBV serology can support neuroinflammatory reasoning, but the association with multiple sclerosis is not a complete causal story. Keep antibody results beside the clinical history, examination and established work-up rather than turning exposure into diagnosis.
MOGAD maintenance treatment is specialist, but the timing lesson is concrete. Early oral corticosteroids can reduce relapse risk, with the spreadsheet naming about 12.5 mg/day and a five-month practical target after a first attack before benefit attenuates.
Save the neuroscience funding report for policy-aware learning rather than immediate bedside action. It links proposed NIH reductions, the BRAIN Initiative funding cliff and prior authorisation burden to future neurological treatment access and research-supported care.
This is mainly for applicants rather than clinicians looking for bedside decisions. It still has a good human factors point: programme choices should include commute, support network, patient population and life outside work, not reputation alone.
Rising head CT use is not the same as better neuroimaging care. Use the trend data as an audit prompt: age, rural residence, race and regional pathways can all alter who receives emergency CT head imaging.
When clinic attention slips or irritation starts to colour the consultation, this quieter neurology piece is worth keeping for later. It is less about diagnosis than about deliberate listening, narrative medicine and the reminder that community practice can still hold teaching, scholarship and professional connection.
.svg)